1 Surging Stock to Target This Week and 2 We Question

via StockStory
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

NOW Cover Image

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.

But not every company with momentum is a long-term winner, and plenty of investors have lost money betting on short-term fads. On that note, here is one stock with lasting competitive advantages and two best left ignored.

Two Momentum Stocks to Sell:

Tilly's (TLYS)

One-Month Return: +20.4%

With an emphasis on skate and surf culture, Tilly’s (NYSE:TLYS) is a specialty retailer that sells clothing, footwear, and accessories geared towards fashion-forward teens and young adults.

Why Are We Out on TLYS?

  1. Store closures are a headwind for growth and suggest it’s rightsizing operations to optimize sales at existing locations
  2. Suboptimal cost structure is highlighted by its history of operating margin losses

Tilly’s stock price of $4.43 implies a valuation ratio of 37x forward P/E. If you’re considering TLYS for your portfolio, see our FREE research report to learn more.

Illumina (ILMN)

One-Month Return: +20.1%

Pioneering the ability to read the human genome at unprecedented speed and affordability, Illumina (NASDAQ:ILMN) develops and sells advanced DNA sequencing and microarray technologies that allow researchers and clinicians to analyze genetic variations and functions.

Why Does ILMN Worry Us?

  1. Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy
  2. Earnings per share fell by 3% annually over the last five years while its revenue grew, partly because it diluted shareholders
  3. Negative returns on capital show management lost money while trying to expand the business

Illumina is trading at $232.04 per share, or 39x forward P/E. To fully understand why you should be careful with ILMN, check out our full research report (it’s free).

One Momentum Stock to Buy:

ServiceNow (NOW)

One-Month Return: +18.9%

Built on a single code base that processes more than 80 billion workflows and 6.5 trillion transactions annually, ServiceNow (NYSE:NOW) provides a cloud-based platform that helps organizations automate and digitize workflows across departments, from IT and HR to customer service and security.

Why Is NOW a Good Business?

  1. ARR trends over the last year show it’s maintaining a steady flow of long-term contracts that contribute positively to its revenue predictability
  2. Fast payback periods on sales and marketing expenses allow the company to invest heavily and onboard many customers concurrently
  3. Robust free cash flow margin of 33.4% gives it many options for capital deployment

At $139.92 per share, ServiceNow trades at 8.3x forward price-to-sales. Is now a good time to buy? See for yourself in our in-depth research report, it’s free.

High-Quality Stocks for All Market Conditions

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article